{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T11:25:19Z","timestamp":1758799519554,"version":"3.44.0"},"reference-count":8,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["PCN Reports"],"published-print":{"date-parts":[[2025,9]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Anorexia nervosa (AN), comorbid with autism spectrum disorder (ASD), poses significant treatment challenges due to cognitive rigidity, poor insight, and frequent nonadherence to pharmacological interventions. Although second\u2010generation antipsychotics (SGAs) have been used off\u2010label in AN, evidence for long\u2010acting injectable (LAI) formulations remains scarce, particularly in adult patients with neurodevelopmental disorders.<\/jats:p><\/jats:sec>Case Presentation<\/jats:title>We report the case of a 27\u2010year\u2010old woman with severe AN and comorbid ASD who exhibited repeated hospitalizations due to critical underweight and persistent refusal of oral medications. Cognitive assessment revealed mild intellectual disability (IQ 56). The patient demonstrated obsessive\u2010compulsive traits and extreme rigidity toward food intake, and was resistant to multiple oral antipsychotics. While risperidone was tolerated, poor adherence limited its efficacy. After obtaining informed consent, LAI paliperidone palmitate was initiated (initial dose 25\u2009mg, increased to 50\u2009mg monthly). Following a short period of psychoeducation and lifestyle intervention, the patient maintained psychiatric and nutritional stability over a 3\u2010year outpatient follow\u2010up without rehospitalization. Her body mass index stabilized at approximately 24\u2009kg\/m2<\/jats:sup>. No severe adverse effects were reported.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>This case highlights the potential role of LAI paliperidone palmitate in managing treatment\u2010refractory AN with comorbid ASD and intellectual disability, particularly in patients with poor adherence and prominent obsessive traits. Although antipsychotics are not standard for AN, LAI formulations may offer pragmatic, sustainable benefits in selected cases. Further studies are warranted to assess long\u2010term safety and efficacy in this population.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pcn5.70161","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T04:49:32Z","timestamp":1752468572000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long\u2010acting injectable paliperidone palmitate for severe anorexia nervosa and comorbid autism spectrum disorder: A case report"],"prefix":"10.1002","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9054-1692","authenticated-orcid":false,"given":"Yuhei","family":"Mori","sequence":"first","affiliation":[{"name":"Department of Neuropsychiatry School of Medicine, Fukushima Medical University Fukushima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8430-9030","authenticated-orcid":false,"given":"Yuhei","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry School of Medicine, Fukushima Medical University Fukushima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry School of Medicine, Fukushima Medical University Fukushima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,7,13]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-2436-9552"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40337-023-00941-6"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001984"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000369978"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0278189"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-024-06372-9"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/eat.24311"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/erv.2941"}],"container-title":["Psychiatry and Clinical Neurosciences Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pcn5.70161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:42:09Z","timestamp":1758796929000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pcn5.70161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,13]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/pcn5.70161"],"URL":"https:\/\/doi.org\/10.1002\/pcn5.70161","archive":["Portico"],"relation":{},"ISSN":["2769-2558","2769-2558"],"issn-type":[{"type":"print","value":"2769-2558"},{"type":"electronic","value":"2769-2558"}],"subject":[],"published":{"date-parts":[[2025,7,13]]},"assertion":[{"value":"2025-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70161"}}